Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Really looks like a real winner... ??. Only down 40%+ today.
Is something brewing here? Bid is currently at $0.0142. Highest it’s been in a while...
Holding nicely on very low volume.
If you can’t afford to lose it, go. If like like to play single numbers on roulette, stay.
95% change of losing everything, 3% chance of breaking even and a 2% chance of a 10 bagger...
I’m holding but with the expectation I lose my full investment.
Remember these are rough translations from Korean via google...
'Interleukin-12' products include Alpha Holdings,
KOSDAQ listed company Alpha Holdings acquired US biopharmaceutical research and development company, Oncocek, and clinical trial of melanoma and triple negative breast cancer
And it is proceeding smoothly.
Alpha Holdings will hold an investor briefing for institutional investors at the Korea Exchange in Seoul,
We have disclosed candidate substances and clinical statuses for expansion of Bio Division, which is most focused on.
Alpha Holdings acquired Nasdaq-listed Oncosec in September of this year. Oncosec is a company that develops anti-cancer drugs using Interleukin-12.
Merck, melanoma, and triple-negative breast cancer in the United States.
Alpha Holdings recognized the need for interleukin-12 because of the high incidence of untreated immune system inhibitors.
According to Oncocek, untreated rates of immune-killing inhibitors are 60-80% for melanoma, 95% for triple-negative breast cancer, and 79-83% for lung cancer
.
Kim Sun-woo, managing director of Alpha Holdings, said that interleukin-12 has an advantage that can be applied to patients who did not receive primary treatment
There is a substance that immune cells transmit signals to each other, and they are exploiting that point to develop immune cancer drugs.
Dr. Kim is also vice president of Oncocese, Dr. Robert Asiworth, who has recently approved 12 new drugs in the US Food and Drug Administration (FDA).
And 80% or more of them are responsible for production management such as R & D, clinical development, licensing and medical device development.
.
Oncosec is currently conducting two phase 2 clinical trials for melanoma and triple negative breast cancer in the US, Canada and Australia,
When clinical 2b is completed at the end of next year, it is planned to be marketed in 2020. The clinical trials for triple-negative breast cancer are expected to be completed in 2020.
Kim Young-sun, Alpha Holdings' CEO, became the largest shareholder in investment in Oncosec, which is in clinical trials with Merck, a global pharmaceutical company.
Said it plans to establish a company called Alpha USA in San Francisco to boost its bio business in the United States.
Alpha Holdings expands oncosec pipeline to lung cancer ... Melanoma Clinical Phase 2 Cruising
Oncosec, the largest shareholder of Alpha Holdings, will enter the lung cancer treatment market with its immunotherapeutic drug Interleukin-12 (IL-12).
Clinical trial 2b for melanoma cancer is also underway and it is expected to be available early in 2020.
The company plans to expand its pipeline (new drug candidates) to the market for large-scale lung cancer by launching a new product on March 3
To this end, it is developing a dedicated electric perforation device (ImmunoPulse platform).
In the case of lung cancer, the preclinical phase and clinical phase 1 are already completed in different indications,
"The details will be decided by consultation with the US Food and Drug Administration (FDA) and will be officially announced at the time of confirmation.
Oncocek injects immunomodulators directly around the cancer cells. Since then, the patented electric punching technology,
Then, it is injected into cancer cells and expressed locally. It is the way that the immune antibody empowers itself to fight cancer cells.
The technology of Oncocek is attracting attention because Merck (product name Kit Luda), BMS (product name Honey · obdibo) which is the first immune barrier inhibitor big medicine of cancer treatment attracts attention
This is because it is a second-line immunotherapy for rare-disease patients who have not been treated. In fact, most of the major clinical trials use interleukin-12 with Kitroda
And the like.
Among the currently available pipelines, melanoma is the most rapid indication for clinical progression. The Keynote-695 for the melanoma 3-4 severe patients
In phase 2b, the company will ask the FDA to appoint a fast track dedicated to rare drugs next year. By the end of next year,
We will go on sale early. Alfa USA, a subsidiary of the US, has also been established to strengthen marketing and strengthen the BT (biotech) business.
Keynote-890, a triple-negative breast cancer pipeline, began recruiting patients on the first day of the month for Phase 2 clinical trials. The results are expected to be drawn up at the end of next year
Initial data will be released in the first half of next year. OMS-131, a two-head cancer pipeline, is expected to enter Phase 2 clinical trials by delivering patients early next year.
Alpha Holdings also accepted that it has a low stake in Oncocec. Alpha Holdings, the largest shareholder in Oncocek, owns 15.65%
All. As major shareholders are willing to exercise the call option granted to convertible bonds (CB), the shareholding rate should be raised to 20%
It is a concept of strengthening.
Don’t most conferences restrict you from announcing data prior to conference?
Edit: SITC states “The data in the abstract must not be published prior to the SITC 33rd Annual Meeting.”
So they’ll announce on conference call but not publish?
Welcome back Sal!
Not ash but $12-$15 is a real possibility but I hate to call it realistic.
Agree, market is saying it is a long ways from a sure thing. I feel we are close but have quit keeping track of how many times I’ve been wrong on ONCS.
I’ve been in and out since 2012. Long and strong now but patient and tempered expectations.
Only thing I like about the PR..... “Additional details of the collaboration were not disclosed.” Ho hum other than that.
https://coi.asco.org/Report/ViewAbstractCOI?id=178747
Not sure there’s anything valuable but interesting nonetheless.
I’ll pay you $3 for your shares doc
Don’t get too excited just yet about a partnership. It’s more than likely going to be partnership similar to the partnership with Merck. I may be wrong and hope I am but let’s not get ahead of ourselves. Regardless, exciting times to come!
AVXS just got paid 8 billion for 9 patients.
Looks like no one is willing to give up 26,000 shares at $1.85 that someone is wanting to buy.
Thanks!! Nothing new or surprising but conformation for sure. Excited to see if more patient data will be shared. The TIL density of 5%+ is huge!
I believe the embargo lasts until the morning of April 15th.
Promise land, here we come!
Thank you for the response! Cancer treatment is developing very rapidly and I appreciate you sharing your knowledge.
Agreed! Not getting my hopes up but EOD on a Friday is intriguing.
Rough estimate but volume was around 100,000 for the period before the mini breakout.
Hschlauch- Any thoughts on the linked abstract that shows OX40 and IL-12 work together in mice.
https://www.ncbi.nlm.nih.gov/pubmed/18250420/
Am curious to hear an educated opinion.
Part of the shorting is very likely to be connected to the share offering. 17.3 million shares for those purchasers that could instantly be sold at a profit.
Another great day! As we all know this is a great stock!
What does this offering mean for interim PISCES data? Seems to me it will be positive if they are doing a raise.
$ONCS pricing of an underwritten public offering of 13,333,334 shares of its common stock at a price of $1.50 per share, with expected gross proceeds of approximately $20 million
Just added 3,200 shares @$1.55!
I got my letter from Carter Terry 2 weeks ago. Definitely weird and ended up in the trash. Included a letter about them being long term holders and the most recent prospectus...
Definitely a lot of motivation to be successful!
No one would care. Avatar is a leech.
No. Would be a complete waste of his time... hard to boot a guy from a position he’s never held.
There’s been complaints on this board for years about their website. Happy to know that they were all right and it did help the PPS!!
Kykkern,
Wasn’t much of a lie was it??
2018 will be a solid year for ONCS!
Off to a good start of the new year and hitting $2 by Friday. Tax selling over and momentum heading into March. This stock has always struggled to maintain momentum but as we get closer to validation this could change quickly!
Positive data in March/April and a financial commitment from Merck is a guarantee from previous filling.
Really looking forward to the next 2 weeks with $ONCS. I think we’ll see $2 by January 5th. Would make a nice setup for the run up to PISCES data in March.
It relates specifically to: https://www.sec.gov/Archives/edgar/data/1444307/000149315217004995/ex99-1.htm
As to what exactly it is, who knows exactly but I would guess you could speculate and get close without exact amounts.
I’m liking this complete switch from the past. The company appears to be focused on the stock price which I don’t recall seeing in the last 4 years. If this threatens to drop below $2 something positive happens.
Let the clinical people focus on trials and a CEO that is cognizant of the investors. I’m sure it’s purely to keep institutions happy but a positive for retail.